Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.63 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29584617 | 1.00 | HDAC6 (0.69) | HDAC6HDAC1HDAC8CES2CES1 | |
| SCHEMBL3945341 | 0.94 | HDAC6 (0.62) | HDAC6HDAC1HDAC8CES2CES1 | |
| SCHEMBL5909363 | 0.85 | HDAC8 (0.83) | HDAC6HDAC8MEN1KMT2AKDM4E | |
| SCHEMBL30147517 | 0.85 | NPC1 (0.60) | HDAC6HDAC1HDAC8NPC1RAB9A | |
| SCHEMBL30147643 | 0.83 | HDAC6 (0.49) | HDAC6HDAC1HDAC8CES2CES1 | |
| SCHEMBL30986828 | 0.82 | HDAC6 (1.00) | HDAC6HDAC1HDAC8CES2CES1 | |
| SCHEMBL29379935 | 0.82 | HDAC6 (1.00) | HDAC6HDAC1HDAC8CES2CES1 | |
| SCHEMBL28885353 | 0.82 | HDAC6 (1.00) | HDAC6HDAC1HDAC8CES2CES1 | |
| SCHEMBL8762392 | 0.81 | LMNA (0.65) | HDAC6HDAC1CES2CES1MEN1 | |
| SCHEMBL12793832 | 0.81 | GPR139 (0.64) | HDAC6HDAC1CES2CES1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274825-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| CN-115873022-A | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-03-31 | — | — | CN | claimed |
| CN-110678472-B | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-01-24 | — | — | CN | claimed |
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | claimed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | claimed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | claimed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | claimed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | claimed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | claimed |
| EP-4612134-A1 | DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-120004754-A | Preparation method of high-purity N-methyl halogenated benzamide | 福州大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-119751480-A | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical compositions thereof, and combinations with anticancer agents | ITEOS比利时公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119604488-A | Protein tyrosine kinase inhibitor and medical application thereof | 苏州必扬医药科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119241559-A | Quinazoline macrocyclic compound serving as HPK1 kinase inhibitor and preparation method and application thereof | 深圳市新樾生物科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1633347-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004110434-A1 | 2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| CN-1157365-C | Monoamine uptake inhibitors for the treatment of CNS disorders | �Ʒ� | 2004-07-14 | — | — | CN | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| CN-1341094-A | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER PROD INC (US) | 2002-03-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | HDAC6 940/4885HDAC1 170/4885HDAC8 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.